University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial

Simple item page
dc.contributor.authorRECOVERY Collaborative Group
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Evaluationen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.date.accessioned2021-05-19T10:33:01Z
dc.date.available2021-05-19T10:33:01Z
dc.date.issued2021-02-13
dc.descriptionFunding UK Research and Innovation (Medical Research Council) and National Institute of Health Research. Acknowledgments Above all, we would like to thank the thousands of patients who participated in this study. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at 176 NHS hospital organisations across the UK, supported by staff at the NIHR Clinical Research Network, NHS DigiTrials, Public Health England, UK Department of Health and Social Care, Intensive Care National Audit and Research Centre, Public Health Scotland, National Records Service of Scotland, Secure Anonymised Information Linkage at University of Swansea, and the NHS in England, Scotland, Wales, and Northern Ireland. The RECOVERY trial is supported by a grant to the University of Oxford from UK Research and Innovation (Medical Research Council) and NIHR (MC_PC_19056) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill & Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical Research Council (MC_UU_0002/14) and an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. AbbVie contributed some supplies of lopinavir–ritonavir for use in this study. Tocilizumab was provided free of charge for this study by Roche Products. REGN-COV2 was provided free of charge for this study by Regeneron. The views expressed in this publication are those of the authors and not necessarily those of the NHS, UK Research and Innovation, the NIHR, or the UK Department of Health and Social Care. The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industryen
dc.description.statusPeer revieweden
dc.format.extent8
dc.format.extent847049
dc.identifier187262223
dc.identifier0f2680cc-f50a-4df5-a10f-253f4eea982d
dc.identifier33545096
dc.identifier85100615475
dc.identifier.citationRECOVERY Collaborative Group 2021, 'Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial', The Lancet, vol. 397, no. 10274, pp. 605-612. https://doi.org/10.1016/S0140-6736(21)00149-5en
dc.identifier.doi10.1016/S0140-6736(21)00149-5
dc.identifier.iss10274en
dc.identifier.issn0140-6736
dc.identifier.otherORCID: /0000-0002-1397-4272/work/88320190
dc.identifier.otherPubMedCentral: PMC7884931
dc.identifier.otherORCID: /0000-0003-3812-7026/work/188766559
dc.identifier.urihttps://hdl.handle.net/2164/16496
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85100615475&partnerID=8YFLogxKen
dc.identifier.vol397en
dc.language.isoeng
dc.relation.ispartofThe Lanceten
dc.subjectAzithromycin/therapeutic useen
dc.subjectCOVID-19/mortalityen
dc.subjectFemaleen
dc.subjectHospital Mortalityen
dc.subjectHospitalizationen
dc.subjectHumansen
dc.subjectLength of Stayen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectSurvival Rateen
dc.subjectTreatment Outcomeen
dc.subjectUnited Kingdomen
dc.subjectCOVID-19 Drug Treatmenten
dc.subjectR Medicineen
dc.subjectGeneral Medicineen
dc.subjectMedical Research Council (MRC)en
dc.subjectMC_UU_0002/14en
dc.subjectNational Institute for Health Research (NIHR)en
dc.subjectNIHR-SRF-2015-08-001en
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleAzithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trialen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Recovery_Collaborative_group_Azithromycin_patients_lancet_vor.pdf
Size:
827.2 KB
Format:
Adobe Portable Document Format
Download

Collections

All research